Researchers from Arkuda Therapeutics reported the discovery and preclinical evaluation of novel oxazoline enhancers of cellular progranulin (PGRN) secretion as candidates for cognition disorders therapy. Phenotypic screening of a diverse library of compounds was applied with the aim of identifying structures that effectively enhanced PGRN release. The lead hits were optimized and assessed in an immortalized murine microglial cell line (BV-2).